BNTC
Benitec Biopharma Inc.
There isn't enough reported data to score BNTC yet.
LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
BNTC Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Unavailable | |
| Strong |
BNTC's balance sheet is currently strong, but its profitability is under pressure. There isn't enough data to rate its revenue and cash flow.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
BNTC PE Valuation
BNTC has no meaningful PE right now: it lost money over the past year.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
BNTC Forward outlook
There aren't enough analyst estimates for BNTC to show an outlook.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
BNTC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$0.98 | +$0.28 |
BNTC is still losing money, but far less than before: $0.98 per share over the past year, against $62.37 at its worst in early 2020.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over BNTC in the latest year-over-year earnings comparison.
BNTC Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2023 | $54K | +13% |
| Q4 2022 | $14K | -44% |
| Q1 2022 | $48K | +4700% |
| Q4 2021 | $25K | +2400% |
| Q1 2021 | $1K | -97% |
| Q4 2020 | $1K | -99% |
| Q3 2020 | $55K | +64% |
BNTC's revenue is shrinking: $0 last quarter.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2023 | -65000% | N/A |
| Q1 2023 | -8039% | -831 points |
| Q4 2022 | -40071% | -20731 points |
| Q1 2022 | -7208% | +372092 points |
| Q4 2021 | -19340% | +306560 points |
| Q2 2021 | -192750% | -185211 points |
| Q1 2021 | -379300% | -376558 points |
| Q4 2020 | -325900% | -322367 points |
BNTC's operating margin was −65000% last quarter, down 45660 points from the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY's revenue has grown year over year for 14 quarters in a row: $24.4B last quarter, up 39% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY's operating margin was 34% last quarter, down 6.6 points from the same quarter a year ago.
BNTC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$5M | +$3.2M |
| Q1 2026 | -$4.5M | -$1.4M |
| Q3 2025 | -$3.4M | +$1.2M |
| Q2 2025 | -$8.2M | -$4.9M |
| Q3 2024 | -$4.6M | -$9K |
| Q4 2023 | -$5.4M | +$478K |
| Q3 2023 | -$4.6M | -$532K |
| Q1 2023 | -$4M | -$607K |
LLY has the stronger cash trend. Its trailing FCF is up 259% versus its history, compared with BNTC at down 39%.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY generated $19.7B in free cash flow over the past year, up 112% from the year before.
BNTC Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +7.4% | +3.4M shares |
| 1 year | +28% | +10.8M shares |
| 3 years | +7634% | +48.7M shares |
| 5 years | +19499% | +49.1M shares |
BNTC has 49M diluted shares, up 28% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2020 | — |
| Q4 2019 | — |
| Q3 2019 | — |
| Q2 2019 | — |
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over BNTC on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
BNTC Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2019 | -4.5x | Net Cash |
BNTC has more cash than debt.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
BNTC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 40.7 | Neutral |
| Stochastic | 20.3 | Neutral |
BNTC's weekly RSI is 41 (neutral) and its Stochastic is 20 (neutral).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
BNTC PE vs Healthcare Sector
BNTC has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
BNTC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $8.95 | 1.6% above |
| 20 week MA | $11.1 | 18% below |
| 50 week MA | $11.5 | 21% below |
| 100 week MA | $12.3 | 26% below |
| 200 week MA | $8.98 | 1.2% above |
BNTC's trend is mixed: it's above two of its five weekly moving averages, and 1.2% above its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over BNTC on trend strength, trading above more of its moving averages.
BNTC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $116.5 | $52.5 | -55% |
| 2021 | $52.5 | $50.7 | -3.6% |
| 2022 | $50.7 | $2.94 | -94% |
| 2023 | $2.94 | $3.23 | +9.9% |
| 2024 | $3.23 | $12.0 | +272% |
| 2025 | $12.0 | $13.1 | +9.2% |
| 2026 YTD | $13.1 | $9.09 | -31% |
BNTC's yearly returns have swung widely, from +272% in 2024 to −94% in 2022. It's down 31% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over BNTC on returns for 2026, with the stronger performance.